Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2013

View Archived Issues

Vismodegib + FOLFOX evaluated in gastroesophageal carcinoma

Astex Pharmaceuticals presents phase I results for AT-13387 in GIST

Sorafenib tested in patients with esophageal and gastroesophageal junction cancer

German university presents novel plasmin inhibitors

New acid ceramidase inhibitors patented by CSIC and the Universitat de Barcelona

Merck & Co. synthesizes new DPP-IV inhibitors

New inhibitors of pim-1, pim-2 and/or pim-3 presented by CNIO

Researchers at Tempero Pharmaceuticals design new HDAC9 inhibitors

Rottapharm synthesizes novel EP4 receptor antagonists

Lupin presents new PKM2 activators

Phase III Oral-lyn dossier submitted to Indian government for marketing approval

Gilead initiates phase III program for tenofovir alafenamide in HIV

Novel vitamin E derivative suppresses oxidative stress in animal models of traumatic injury

Amarin launches Vascepa in the U.S.

Vanda Pharmaceuticals reports results from second phase III RESET study

Biogen Idec reports topline results from phase III peginterferon beta-1a trial

Dymista obtains approval in Europe

Curis doses first patient in phase I trial of CUDC-907

Selepressin is beneficial in patients with septic shock

Preclinical studies suggest broad potential for GFT-505 in cirrhosis

Results reported from phase III Japanese studies of KRN-125

Biodel reports topline results from study of ultra-rapid-acting insulin analogue candidates

Orexo and AstraZeneca sign research agreement

Exelixis launches Cometriq in the U.S.

Eurocine Vaccines developing Immunose FLU for pediatric market

Development discontinued of limaprost alfadex for carpal tunnel syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...